International Liver Congress 2014 Meeting Highlights

*Graham R. Foster,1 **Jean-Michel Pawlotsky2,3

1. Queen Mary University of London, Institute of Cell and Molecular Science, London, UK
2. National Reference Center for Viral Hepatitis B, C, and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France
3. INSERM U955, Créteil, France *Correspondence to
**Correspondence to

Disclosure: Graham Foster has received funding from AbbVie, Gilead Sciences, Roche, Merck, Janssen, Idenix, Novartis, and GSK. Jean-Michel Pawlotsky has received research grants from Gilead Sciences and has served as an advisor for Abbott, AbbVie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, and Roche.
Support: The authors would like to thank Dr Caroline Charles for medical writing assistance with this manuscript.
Received: 04.07.14  Accepted: 05.08.14
Citation: EMJ Hepatol. 2014;1(Suppl 1):2-15.


The main objective of chronic hepatitis C virus (HCV) management is to provide high viral eradication rates with acceptable toxicity. The new era of direct-acting antivirals (DAAs) has considerably changed the standard of care, and each main congress provides new and insightful information. Very encouraging clinical data on interferon and ribavirin-free combinations with oral DAAs were recently made available, and comprise over 90%, and up to 100%, of infection cure rates for treatment-naïve patients; consistent results can also be observed across many difficult-to-cure subpopulations such as patients with advanced liver disease, HIV-coinfected patients, and patients in the post-liver transplant setting, which could, therefore, no longer be considered as difficult-to-cure populations. This review will summarise the highlights of the 2014 International Liver Congress that took place from 9th-13th April in London, UK, and will provide an outlook on the future of HCV treatment.

Download (PDF, 217KB)

Comments are closed.